In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Novartis buys back Speedel to boost its pipeline

Executive Summary

After spinning out Speedel (cardiovascular and metabolic diseases) in 1998, Novartis is buying back the now-public company. Novartis has raised its current 9.7% equity stake to 61.4% through the acquisition of about 4mm registered shares from five major shareholders, including company CEO Alice Huxley who held a 21.5% stake. The investors received a total of CHF525.4mm ($509mm) or about CHF130 per share (a 98% premium).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Cash

Related Companies